You have read all your free articles, to continue reading subscribe to read the rest of this content.
The company has entered a new five-year SEK 1 500 million loan facility with three of the largest banks in Scandinavia for continued growth. The revolving credit facility of SEK 1 500 million is signed with DNB, Handelsbanken and Swedbank and will serve as an additional resource to facilitate Already a subscriber Login…
The Issue will provide the company with SEK 200 million before transaction costs. Ascelia Pharma intends to use the net proceeds from the Issue for (i) financing the Phase II study for the oral chemotherapy drug candidate Oncoral, (ii) accelerating activities towards the commercialization of the Already a subscriber Login…
Sound Bioventures, a new Scandinavia-based life sciences venture capital firm, has announced the first close of its first fund. The fund has a geographic footprint on both sides of the Atlantic and will invest in European and US-based private biotech companies supporting the clinical development Already a subscriber Login You…
Just before Christmas, the Norwegian company announced that it has received support from Oslo County of 1.950 million NOK. The funding will support optimization of the synthesis of our two lead compounds, APC148 and APC247. The program will define the optimal characteristics of the substances thaAlready a subscriber Login You…
